Published in Ther Drug Monit on October 01, 1997
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther (2011) 3.09
Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol (2010) 2.15
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther (2014) 1.84
Opioid metabolism. Mayo Clin Proc (2009) 1.76
Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet (2004) 1.51
Progress in genetic studies of pain and analgesia. Annu Rev Pharmacol Toxicol (2009) 1.43
Guidelines for maternal codeine use during breastfeeding. Can Fam Physician (2009) 1.21
Applications of CYP450 testing in the clinical setting. Mol Diagn Ther (2013) 1.08
Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Philos Trans R Soc Lond B Biol Sci (2005) 1.04
Role of active metabolites in the use of opioids. Eur J Clin Pharmacol (2008) 0.91
Genetic variability of pain perception and treatment--clinical pharmacological implications. Eur J Clin Pharmacol (2011) 0.84
Role of cytochrome P450 genotype in the steps toward personalized drug therapy. Pharmgenomics Pers Med (2011) 0.83
Pharmacokinetics and intramuscular bioavailability of a single dose of butorphanol in Asian elephants (Elephas maximus). J Zoo Wildl Med (2010) 0.79
Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine. Genomics Proteomics Bioinformatics (2016) 0.76
Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes. Br J Clin Pharmacol (2000) 0.76
In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17β-dihydroexemestane. Pharmacol Res Perspect (2017) 0.75
Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br Med J (1969) 4.21
Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese. Lancet (1989) 2.96
Effect of environmental factors on drug metabolism: decreased plasma half-life of antipyrine in workers exposed to chlorinated hydrocarbon insecticides. Clin Pharmacol Ther (1969) 2.75
Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein. N Engl J Med (1978) 2.68
Disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol (1983) 2.59
Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution. Clin Pharmacol Ther (1971) 2.45
Acetylator phenotype in patients with hydralazine-induced lupoid syndrome. Acta Med Scand (1976) 2.34
Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J (1971) 2.19
Correlation of subjective side effects with plasma concentrations of nortriptyline. Br Med J (1970) 2.13
Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol (1994) 2.09
Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A (1993) 2.08
Determination of morphine, morphine-3-glucuronide and (tentatively) morphine-6-glucuronide in plasma and urine using ion-pair high-performance liquid chromatography. J Chromatogr (1982) 2.07
Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sci (1967) 2.05
Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet (1993) 1.87
A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin Pharmacol Ther (1985) 1.87
Plasma protein binding of tricyclic anti-depressants in man. Biochem Pharmacol (1969) 1.86
Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N Engl J Med (1971) 1.76
10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther (1998) 1.72
Gas chromatographic assessment of the reproducibility of phenazone plasma half-life in young healthy volunteers. Eur J Clin Pharmacol (1974) 1.68
Psychotropic drugs (2). Interaction between monoamine oxidase (MAO) inhibitors and other substances. Proc R Soc Med (1965) 1.67
Validation of observed differences in the utilization of antihypertensive and antidiabetic drugs in Northern Ireland, Norway and Sweden. Eur J Clin Pharmacol (1985) 1.67
Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther (1992) 1.66
Genetic control of nortriptyline kinetics in man: a study of relatives of propositi with high plasma concentrations. J Med Genet (1971) 1.66
Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun (1999) 1.66
CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand (2001) 1.59
High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation. Lancet (1982) 1.46
Hypothermic effect of apomorphine in the mouse. J Pharm Pharmacol (1972) 1.43
Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet (1987) 1.42
Two-fold interindividual variation in plasma protein binding of phenytoin in patients with epilepsy. Clin Pharmacokinet (1977) 1.41
Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther (1992) 1.41
E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther (1981) 1.41
A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age. Clin Pharmacol Ther (2010) 1.38
Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clin Pharmacol Ther (1993) 1.38
Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther (1988) 1.37
Drug utilization 90%--a simple method for assessing the quality of drug prescribing. Eur J Clin Pharmacol (1998) 1.35
New possibilities for adrenergic modulation of ganglionic transmission. Pharmacol Rev (1966) 1.32
Clinical pharmacology and primary health care in Europe--a gap to bridge. The WHO Working Group on Clinical Pharmacology in Europe. Eur J Clin Pharmacol (1990) 1.30
The measurement of drug consumption. Drugs for diabetes in Northern Ireland, Norway and Sweden. Eur J Clin Pharmacol (1975) 1.30
Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol (1995) 1.28
Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther (2001) 1.25
Decreased plasma protein binding of phenytoin in patients on valproic acid. Br J Clin Pharmacol (1979) 1.25
Clinical pharmacology and the provision of drug information. Eur J Clin Pharmacol (1992) 1.25
Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos (2001) 1.23
Comparison of the half-life of antipyrine in plasma, whole blood and saliva of man. Eur J Clin Pharmacol (1976) 1.23
Concentrations of chloroquine and desethylchloroquine in capillary blood dried on filter paper during and after treatment of Tanzanian children infected with Plasmodium falciparum. Trop Med Parasitol (1986) 1.22
Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochem Pharmacol (1985) 1.22
Determination of chloroquine and its desethyl metabolite in whole blood: an application for samples collected in capillary tubes and dried on filter paper. Ther Drug Monit (1985) 1.21
Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther (1995) 1.21
Pharmacokinetics and biological effects of nortriptyline in man. Acta Pharmacol Toxicol (Copenh) (1971) 1.21
Characterization of chloroquine plasma protein binding in man. Br J Clin Pharmacol (1983) 1.21
Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics (1995) 1.20
PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics (1996) 1.17
Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol (2001) 1.17
Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics (1992) 1.16
Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci (1980) 1.13
Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin Pharmacol Ther (1998) 1.12
Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. Br J Clin Pharmacol (1989) 1.12
The disposition of chloroquine in healthy Nigerians after single intravenous and oral doses. Br J Clin Pharmacol (1987) 1.11
Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. Br J Clin Pharmacol (1989) 1.11
Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol (1994) 1.11
Cholinacetylase in innervated and denervated sympathetic ganglia and ganglion cells of the cat. Acta Physiol Scand (1967) 1.06
A comparative study of the metabolism of desmethylimipramine, nortriptyline, and oxyphenylbutazone in man. Clin Pharmacol Ther (1969) 1.06
D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry (1995) 1.05
Chloroquine and desethylchloroquine in plasma, serum, and whole blood: problems in assay and handling of samples. Ther Drug Monit (1985) 1.05
Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden. Br J Clin Pharmacol (1995) 1.04
Indoleamine metabolites in the cerebrospinal fluid of depressed patients before and during treatment with nortriptyline. Clin Pharmacol Ther (1973) 1.03
In vitro activity of chloroquine, the two enantiomers of chloroquine, desethylchloroquine and pyronaridine against Plasmodium falciparum. Br J Clin Pharmacol (1986) 1.03
Gas chromatographic determination of ethosuximide and phensuximide in plasma and urine of man. J Pharm Pharmacol (1973) 1.01
Determination of bioavailability of diazepam in various formulations from steady state plasma concentration data. Clin Pharmacol Ther (1972) 1.01
Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther (1996) 1.00
Initial clinical trial based on biochemical methodology of zimelidine (a serotonin uptake inhibitor) in depressed patients. Clin Pharmacol Ther (1977) 1.00
Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther (1991) 1.00
Steady-state plasma concentrations of alprenolol in man. Eur J Clin Pharmacol (1974) 1.00
Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit (1992) 1.00
Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics (1996) 0.99
Plasma protein binding of diphenylhydantoin in normal and hyperbilirubinemic infants. J Pediatr (1971) 0.99
Genetic polymorphism of cytochrome P4502E1 in a Swedish population. Relationship to incidence of lung cancer. FEBS Lett (1993) 0.98
Inactivation of isoniazid (INH) in Swedish tuberculous patients before and during treatment with para-aminosalicylic acid (PAS). Scand J Respir Dis (1970) 0.98
Pronounced inhibition of noradrenaline uptake by 10-hydroxymetabolites of nortriptyline. Life Sci (1979) 0.97
A pharmacokinetic approach to the treatment of depression. Int Pharmacopsychiatry (1971) 0.97
Nortriptyline and debrisoquine hydroxylations in Ghanaian and Swedish subjects. Clin Pharmacol Ther (1984) 0.96
Oxazepam disposition in uremic patients. Acta Pharmacol Toxicol (Copenh) (1977) 0.96
Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Lett (1998) 0.95
Nonlinearity of amoxicillin absorption kinetics in human. Eur J Clin Pharmacol (1992) 0.95
Weak binding of 10-hydroxymetabolites of nortriptyline to rat brain muscarinic acetylcholine receptors. Life Sci (1984) 0.95
Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl) (1999) 0.95
Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics (1995) 0.94
Problem-oriented drug information: a clinical pharmacological service. Lancet (1983) 0.94
Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes. Clin Pharmacol Ther (1984) 0.93
Plasma disappearance of transplacentally transferred diphenylhydantoin in the newborn studied by mass fragmentography. Clin Pharmacol Ther (1974) 0.93
The hypnotic efficacy of doxylamine. Clin Pharmacol Ther (1967) 0.93
Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther (1998) 0.92
Genetic polymorphism of human CYP2E1: characterization of two variant alleles. Mol Pharmacol (1997) 0.92
Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol (1991) 0.91